‘Big Short’ Investor Michael Burry Thinks Biden’s Student Loan Forgiveness Will Mean ‘Terrible Consequences For America’
‘The Big Short’ investor Michael Burry believes the student debt problem itself has been built on bad choices…
Supreme Court Student Loan Forgiveness Case Starts This Week: What Investors And Students Should Know
American college students and investors exposed to student loan stocks will be watching the beginning of a new Supreme Court case involving President Joe Biden's student debt relief plan this week.
Citigroup Maintains Neutral on Navient, Raises Price Target to $19
Citigroup analyst Arren Cyganovich maintains Navient (NASDAQ:NAVI) with a Neutral and raises the price target from $15 to $19.
Earnings Scheduled For January 24, 2023
Companies Reporting Before The Bell
• GATX (NYSE:GATX) is expected to report quarterly earnings at $1.44 per share on revenue of $327.63 million.
4 Analysts Have This to Say About Navient
Navient (NASDAQ:NAVI) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish…
Benzinga’s Top Ratings Upgrades, Downgrades For December 1, 2022
Upgrades Northcoast Research upgraded the previous rating for SpartanNash Co (NASDAQ:SPTN) from Neutral to Buy. SpartanNash earned $0.55…
Morgan Stanley Maintains Underweight on Navient, Lowers Price Target to $14
Morgan Stanley analyst Jeffrey Adelson maintains Navient (NASDAQ:NAVI) with a Underweight and lowers the price target from $14.5 to $14.
Boeing, Seagate, Chipotle And Other Big Losers From Wednesday
U.S. stocks closed mostly lower on Wednesday, with the Nasdaq Composite dropping over 200 points. Here is the list of some big stocks recording losses in the previous session.
Regeneron Pharmaceuticals To $851? Here Are 5 Other Price Target Changes For Friday
Morgan Stanley raised the price target on Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) from $625 to $851. Morgan Stanley analyst Matthew Harrison also upgraded the stock from Equal-Weight to Overweight. Regeneron Pharmaceuticals shares rose 0.9% to $714.99 in pre-market trading.